Relative free energy of binding and binding mode calculations of HIV‐1 RT inhibitors based on dock‐MM‐PB/GS

Tetrahydroimidazo‐[4,5,l‐jk][1,4]‐benzodiazepin‐2‐(1H)‐one (TIBO) derivatives are important nonnucleoside human immunodeficiency virus‐1 reverse transcriptase inhibitors (NNRTI). Several TIBO derivatives have shown high potency to inhibit reverse transcriptase (RT) and one (Tivirapine) has entered into clinical trials. The free energy of binding (FEB) is a numerical way to express the binding affinity of a ligand to its receptor and has been applied in screening candidates in rational drug design. In this work, the FEB of 42 TIBOs in RT was studied. Relative FEB is expressed in the form of a linear combination of vdW, electrostatic, solvation, and nonpolar solvation energy terms. The predicted FEB activity of the TIBOs studied has a good correlation (r2 = 0.8680, q2 = 0.8298) with respect to the experimental activity (pIC50). Based on the data reported here, the Finite Difference Poisson Boltzmann with a Gaussian Smooth Dielectric Constant Function method (PB/GS) solvation energy term is very important in predicting the binding affinity of TIBOs in RT. In summary, the Dock‐Molecular Mechanics (MM)‐PB/GS method is a promising technique in predicting ligand/receptor binding affinity and it can be used to screen relatively large sets of molecules in a reasonable amount of computer time. Proteins 2004. © 2004 Wiley‐Liss, Inc.

[1]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution , 1995 .

[2]  R. Pauwels,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TIBO) derivatives. , 1991, Journal of medicinal chemistry.

[3]  Michael Wiese,et al.  Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methoxyphenyl)-1,4- dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: A molecular modeling study , 1999, J. Comput. Aided Mol. Des..

[4]  E. Arnold,et al.  HIV reverse transcriptase structure-function relationships. , 1991, Biochemistry.

[5]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[6]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[7]  Erik De Clercq,et al.  Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) analogues , 1999 .

[8]  Rajni Garg,et al.  Comparative Quantitative Structure—Activity Relationship Studies on Anti-HIV Drugs , 2000 .

[9]  Ricardo L. Mancera,et al.  A new quantum stochastic tunnelling optimisation method for protein–ligand docking , 2003 .

[10]  C. Dominguez,et al.  HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. , 2003, Journal of the American Chemical Society.

[11]  U. Singh,et al.  A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .

[12]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[13]  R. Pauwels,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2. , 1991, Journal of medicinal chemistry.

[14]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[15]  Bernard R Brooks,et al.  A core-weighted fitting method for docking atomic structures into low-resolution maps: application to cryo-electron microscopy. , 2003, Journal of structural biology.

[16]  M J Kukla,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo-[4,5,1-jk][1,4]benzodiazepin- 2(1H)-one (TlBO) derivatives. 4. , 1995, Journal of medicinal chemistry.

[17]  Li Wang,et al.  Hierarchy of protein assembly at the vertex ring domain for yeast vacuole docking and fusion , 2003, The Journal of cell biology.

[18]  Pierre L'Ecuyer,et al.  Implementing a random number package with splitting facilities , 1991, TOMS.

[19]  S. Hannongbua,et al.  Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis. , 2000, Journal of molecular graphics & modelling.

[20]  G R Marshall,et al.  3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. , 1994, Drug design and discovery.

[21]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[22]  J L Sullivan,et al.  Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. , 1991, The Journal of infectious diseases.

[23]  A. Debnath,et al.  Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis. , 1999, Journal of medicinal chemistry.

[24]  W L Jorgensen,et al.  Prediction of drug solubility from Monte Carlo simulations. , 2000, Bioorganic & medicinal chemistry letters.

[25]  A. Carotti,et al.  Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs). , 1999, Bioorganic & medicinal chemistry.

[26]  M. Miranda,et al.  Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk][1,4]benzodiazepin-2(1H)-one (TIBO) derivatives. 3. , 1991, Journal of medicinal chemistry.

[27]  M L Lamb,et al.  Monte Carlo calculations on HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor 8-Cl TIBO: contribution of the L100I and Y181C variants to protein stability and biological activity. , 2000, Protein engineering.

[28]  S. Broyde,et al.  Stereochemical, structural, and thermodynamic origins of stability differences between stereoisomeric benzo[a]pyrene diol epoxide deoxyadenosine adducts in a DNA mutational hot spot sequence. , 2001, Journal of the American Chemical Society.

[29]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[30]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[31]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[32]  P A Kollman,et al.  Prediction of the binding free energies of new TIBO-like HIV-1 reverse transcriptase inhibitors using a combination of PROFEC, PB/SA, CMC/MD, and free energy calculations. , 1999, Journal of medicinal chemistry.

[33]  E. Pedersen,et al.  Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom , 1999, Antiviral chemistry & chemotherapy.

[34]  Henri Moereels,et al.  Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors , 1995, Nature Structural Biology.

[35]  J. Andrew Grant,et al.  A smooth permittivity function for Poisson–Boltzmann solvation methods , 2001, J. Comput. Chem..

[36]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[37]  D. Richman,et al.  BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.

[38]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[39]  Jianping Ding,et al.  Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. , 1996, Drug design and discovery.

[40]  J. Buolamwini,et al.  CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: exploration of a binding mode at the active site. , 2002, Journal of medicinal chemistry.

[41]  Jared Spidel,et al.  Kinetic and docking studies of the interaction of quinones with the quinone reductase active site. , 2003, Biochemistry.

[42]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[43]  Opera Ti,et al.  3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results. , 1994 .

[44]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[45]  I. Kuntz,et al.  Inclusion of Solvation in Ligand Binding Free Energy Calculations Using the Generalized-Born Model , 1999 .

[46]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[47]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Margaret A. Johnson,et al.  A novel modeling protocol for protein receptors guided by bound-ligand conformation. , 2003, Biochemistry.

[49]  Emil Alexov,et al.  Rapid grid‐based construction of the molecular surface and the use of induced surface charge to calculate reaction field energies: Applications to the molecular systems and geometric objects , 2002, J. Comput. Chem..

[50]  C. Hansch,et al.  Comparative Quantitative Structure−Activity Relationship Studies on Anti-HIV Drugs , 1999 .

[51]  Roger J.-B. Wets,et al.  Minimization by Random Search Techniques , 1981, Math. Oper. Res..

[52]  Atul Purohit,et al.  Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. , 2003, Bioorganic & medicinal chemistry letters.

[53]  Marcela Madrid,et al.  Docking of non‐nucleoside inhibitors: Neotripterifordin and its derivatives to HIV‐1 reverse transcriptase , 2002, Proteins.

[54]  S. Goff,et al.  Retroviral reverse transcriptase: synthesis, structure, and function. , 1990, Journal of acquired immune deficiency syndromes.

[55]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[56]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[57]  William L. Jorgensen,et al.  Analysis of Binding Affinities for Celecoxib Analogues with COX-1 and COX-2 from Combined Docking and Monte Carlo Simulations and Insight into the COX-2/COX-1 Selectivity , 2000 .

[58]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.

[59]  Stanislav Miertus,et al.  Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties. , 2002, Journal of medicinal chemistry.

[60]  Jonathan W. Essex,et al.  Monte Carlo Simulations for Proteins: Binding Affinities for Trypsin−Benzamidine Complexes via Free-Energy Perturbations , 1997 .

[61]  S. Hughes,et al.  Retroviral reverse transcription and integration: progress and problems. , 1992, Annual review of cell biology.

[62]  P. Kollman,et al.  MM-PBSA Applied to Computer-Assisted Ligand Design , 2003 .

[63]  P A Kollman,et al.  An analysis of the interactions between the Sem-5 SH3 domain and its ligands using molecular dynamics, free energy calculations, and sequence analysis. , 2001, Journal of the American Chemical Society.

[64]  J. Gasteiger,et al.  ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES , 1980 .

[65]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[66]  J N Weinstein,et al.  Three-dimensional quantitative structure-activity relationship (QSAR) of HIV integrase inhibitors: a comparative molecular field analysis (CoMFA) study. , 1995, Journal of medicinal chemistry.

[67]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[68]  Prashant V Desai,et al.  Probing the structure of falcipain‐3, a cysteine protease from Plasmodium falciparum: Comparative protein modeling and docking studies , 2003, Protein science : a publication of the Protein Society.

[69]  G Klebe,et al.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. , 1999, Journal of medicinal chemistry.

[70]  R. Zauhar,et al.  Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. , 2000, Journal of medicinal chemistry.

[71]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[72]  A. Debnath,et al.  Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1. , 1994, Journal of medicinal chemistry.